SGLT inhibition: A possible adjunctive treatment for type 1 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 25, Issue 4, 2018, Pages 246-250

  Akturk, Halis Kaan ^a,b   Rewers, Amanda ^a   Garg, Satish K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

canagliflozin; dapagliflozin; diabetic ketoacidosis; empagliflozin; glucose control; Hba1c; hypoglycemia; SGLT 1 inhibitors; SGLT 2 inhibitors; sotagliflozin; type 1 diabetes; weight gain

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE; INSULIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 1 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSIDE;

CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; MYCOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PROOF OF CONCEPT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; ADULT; ANALYSIS; BODY WEIGHT GAIN; CHEMICALLY INDUCED; HYPOGLYCEMIA;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; GLUCOSIDES; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; WEIGHT GAIN;

EID: 85050214288     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000423     Document Type: Review

References (41)

1. Menke A, Orchard TJ, Imperatore G, et al. The prevalence of type 1 diabetes in the United States. Epidemiology (Cambridge, Mass) 2013; 24:773-774.
2. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377:2337-2348.
3. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383:69-82.
4. Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract 2016; 22:220-230.
5. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38:971-978.
6. Garg SK. Expanding treatment options for improving health outcomes in type 1 diabetes. Diabetes Technol Ther 2017; 19:549-551.
7. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37:1815-1823.
8. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The adjunct one treat-To-Target randomized trial. Diabetes Care 2016; 39:1702-1710.
9. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigatorinitiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013; 19:19-28.
10. Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): A double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5:597-609.
11. Hinshaw L, Schiavon M, Dadlani V, et al. Effect of pramlintide on postprandial glucose fluxes in type 1 diabetes. J Clin Endocrinol Metab 2016; 101:1954-1962.
12. Herrmann K, Brunell SC, Li Y, et al. Impact of disease duration on the effects of pramlintide in type 1 diabetes: A post hoc analysis of three clinical trials. Adv Therapy 2016; 33:848-861.
13. Oktay AA, Akturk HK, Jahangir E. Diabetes mellitus and hypertension: A dual threat. Curr Opin Cardiol 2016; 31:402-409.
14. Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 2015; 308:G946-G954.
15. Oktay AA, Akturk HK, Esenboga K, et al. Pathophysiology and prevention of heart disease in diabetes mellitus. Curr Probl Cardiol 2018; 43:68-110.
16. Sternlicht H, Bakris GL. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol 2016; 12:128-129.
17. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60:215-225.
18. Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: A systematic review and metaanalysis. Sci Rep 2017; 7:44128.
19. Takeishi S, Tsuboi H, Takekoshi S. Comparison of tofogliflozin 20mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study. Endocr J 2017; 64:995-1005.
20. Twenty-four week efficacy and safety of Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem2). American Diabetes Association (ADA) Scientific Sessions, San Diego, CA; 2017.
21. Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38:2258-2265.
22. Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017; 40:171-180.
23. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38:412-419.
24. Henry RR, Dandona P, Pettus J, et al. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-h continuously monitored mean glucose and fasting beta-hydroxybutyrate levels in a phase IIa pilot study. Diab Obes Metab 2017; 19:814-821.
25. Tamez HE, Tamez AL, Garza LA, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord 2015; 14:78.
26. Tang W, Leil TA, Johnsson E, et al. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18:236-240.
27. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 2016; 101:3506-3515.
28. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5:864-876.
29. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week openlabel proof-of-concept trial. Diabetes Care 2014; 37:1480-1483.
30. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17:928-935.
31. Famulla S, Pieber TR, Eilbracht J, et al. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Technol Ther 2017; 19:49-60.
32. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128.
33. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644-657.
34. Schnell O, Ryden L, Standl E, Ceriello A. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2017; 16:128.
35. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev 2017; 33:. [Epub 2017 Sep 29]
36. Hine J, Paterson H, Abrol E, et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015; 3:503-504.
37. Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-Transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab 2018; 20:25-33.
38. Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 2017; 60:1385-1389.
39. Peters AL, Henry RR, Thakkar P, et al. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016; 39:532-538.
40. Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-Transporter 2 inhibitors: A meta-Analysis of randomized controlled trials. Diabetes Obes Metab 2017; 19:348-355.
41. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med 2016; 128:409-417.